6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
    40.
    发明授权
    6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders 有权
    6-环烷基 - 吡唑并嘧啶酮用于治疗CNS疾病

    公开(公告)号:US09328120B2

    公开(公告)日:2016-05-03

    申请号:US14511238

    申请日:2014-10-10

    摘要: The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.

    摘要翻译: 本发明涉及式(I)的新型6-环烷基 - 吡唑并嘧啶酮。 其中R1是5或6元芳族杂芳基,R2是任选的取代基,D是任选取代的环戊基,环己基,四氢呋喃基,四氢吡喃基或2-,3-或4-吡啶基,m = 1或2,n是0 ,1或2.新化合物分别用作药物的活性成分或用于制造药物,特别是用于治疗感知,集中,学习或记忆缺陷的病症的药物。 这种情况可能例如与阿尔茨海默病,精神分裂症和其他疾病相关。 新化合物还例如用于制备药物和/或用于治疗这些疾病,特别是与这种疾病相关的认知障碍。 本发明化合物显示PDE9抑制性质。